Table 1.
Characteristics of study participants at diagnosis.
| Values | Range | |
|---|---|---|
| Age on set, years | 49.7 ± 12.3 | (7-79) |
| Male/Female | 102/231 (1:2.3) | |
| Fever | 158 (47.4%) | |
| CK, IU/L (Normal 26-200) |
433.9 ± 1082.8 | (12-10762) |
| Ferritin, ng/mL (Normal 11-306.8) |
793.0 ± 1370.0 | (5.7-11871) |
| Anti-MDA5 antibody | 175 (52.6%) | |
| Anti-ARS antibodies | 158 (47.4%) | |
| Anit-Jo-1 antibody | 79 (23.7) | |
| Anti-PL-7 antibody | 35 (10.5) | |
| Anti-PL-12 antibody | 17 (5.1) | |
| Anti-EJ antibody | 27 (8.1) | |
| Anti-Ro-52 antibody | 113 (33.9%) | |
| FVC% | 74.8 ± 19.2 | (39-140) |
| FEV1% | 71.8 ± 16.9 | (40-112) |
| DLCO% | 54.9 ± 15.5 | (29-100) |
| BALF LYM% | 24.4 ± 23.1 | (0-97) |
| BALF NE% | 50.7 ± 28.2 | (2-99) |
| BALF Mac% | 20.8 ± 15.8 | (1-74) |
| Treatment of MDA5+DM (n, %) | ||
| Glucocorticoids | 175 (100%) | |
| Pulse steroid therapy | 8 (4.6%) | |
| Calcineurin inhibitors | 70 (40.0%) | |
| Cyclophosphamide | 42 (24.0%) | |
| Mycophenolate mofetil | 10 (5.7%) | |
| Treatment of ASS (n, %) | ||
| Glucocorticoids | 158 (100%) | |
| Pulse steroid therapy | 2 (1.3%) | |
| Calcineurin inhibitors | 12 (7.6%) | |
| Cyclophosphamide | 64 (40.5%) | |
| Mycophenolate mofetil | 17 (10.8%) |
FVC%, percentage of the predicted forced vital capacity; FEV1%, percent of forced expiratory volume in the first second; DLCO%, percentage of the predicted diffusion capacity for carbon monoxide; BALF LYM%, percentage of lymphocyte in bronchoalveolar lavage fluid; BALF NE%, percentage of neutrophil in bronchoalveolar lavage fluid; BALF Mac%, percentage of macrophage in bronchoalveolar lavage fluid.